Aclaris Therapeutics Inc (ACRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.93 Million) by net assets ($120.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACRS equity to assets ratio to measure how much of total assets are equity-financed.
Aclaris Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ACRS capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Aclaris Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclaris Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perfect Group Corp Ltd Class A
SHG:603059
|
0.048x |
|
Hangzhou Coco Healthcare Products Co.Ltd.
SHE:301009
|
-0.012x |
|
Wonderful Hi-Tech Co Ltd
TWO:6190
|
0.011x |
|
Brunel International NV
AS:BRNL
|
0.153x |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
0.020x |
|
Junhe Pumps Holding Co Ltd
SHG:603617
|
0.035x |
|
Filatex India Limited
NSE:FILATEX
|
0.155x |
|
NEL ASA ADR/30 NK -20
F:D7GA
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see ACRS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.55 Million | $-20.07 Million | -0.129x | +74.10% |
| 2023-12-31 | $157.18 Million | $-78.33 Million | -0.498x | -45.75% |
| 2022-12-31 | $197.62 Million | $-67.57 Million | -0.342x | -29.42% |
| 2021-12-31 | $197.34 Million | $-52.13 Million | -0.264x | +74.25% |
| 2020-12-31 | $37.65 Million | $-38.63 Million | -1.026x | +25.62% |
| 2019-12-31 | $69.91 Million | $-96.44 Million | -1.380x | -194.38% |
| 2018-12-31 | $215.12 Million | $-100.81 Million | -0.469x | -93.11% |
| 2017-12-31 | $225.26 Million | $-54.66 Million | -0.243x | -18.86% |
| 2016-12-31 | $169.49 Million | $-34.60 Million | -0.204x | +7.27% |
| 2015-12-31 | $92.52 Million | $-20.37 Million | -0.220x | -159.84% |
| 2014-12-31 | $-20.75 Million | $-7.64 Million | 0.368x | -31.48% |
| 2013-12-31 | $-9.16 Million | $-4.92 Million | 0.537x | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more